Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHD

• Alkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been presented.
• The investigational orexin 2 receptor agonist showed clinically meaningful symptom improvement versus baseline, supporting further development in ADHD.
• Safety profile was generally tolerable in healthy volunteers and adult patients; no serious treatment-emergent adverse events were reported.
• A Phase 2 trial is enrolling, with data expected in 2027; the first participant was dosed in September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210700BIZWIRE_USPR_____20260921_BW142041) on September 21, 2026, and is solely responsible for the information contained therein.